57th ASH Annual Meeting and Exposition (December 5-8, 2015): 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Immune Modulation and Microenvironment in Lymphoma

Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents Oral and Poster Abstracts
Oral

Hall E2, Level 2 (Orange County Convention Center)

Moderators:

Grzegorz S. Nowakowski, MD, Mayo Clinic and Salvia Jain, MD, Beth Israel Deaconess Medical Center, Harvard Medical School

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

817

Diffuse Large B-Cell Lymphoma Patient-Derived Xenograft Models Capture Molecular and Biologic Heterogeneity and Inform Therapy

Bjoern Chapuy, MD PhD¹, Honwei Cheng, MD PhD²^*, Akira Watahiki, MD PhD²^*, Matthew D Ducar, PhD³^*, Daniel Gusenleitner, MS⁴^*, Linfeng Chen, PhD¹^*, Margaretha GM Roemer, MS¹^*, Jing Quyang, PhD¹^*, Amanda L Christie, B.S.⁵^*, Liye Zhang, PhD⁴^*, Yuxiang Tan⁴^*, Ryan P Abo, PhD³^*, Frederike Bonin⁶^*, Aaron R Thorner, PhD³^*, Heather H. Sun⁷^*, Geraldine S Pinkus, MD⁷^*, Paul van Hummelen, PhD³^*, Gerald G Wulf, MD⁶, Jon C Aster, MD PhD⁷, David M Weinstock, MD¹, Stefano Monti, PhD⁴^*, Scott J Rodig, MD, PhD⁷, Yuzhuo Wang, PhD²^* and Margaret A. Shipp, MD⁸

¹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Experimental Therapeutics, BC Cancer Agency, Vancouver, Canada
³Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA
⁴Section of Computational Biomedicine, Boston University School of Medicine, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Hematology and Oncology, Georg-August University of Göttingen, Göttingen, Germany
⁷Pathology, Brigham and Women's Hospital, Boston, MA
⁸Dana-Farber Cancer Institute, Boston, MA

4:45 PM

818

CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3

Bindu Varghese, PhD, Jayanthi Menon^*, Luis Rodriguez^*, Kara Olson^*, Pamela Krueger^*, Tammy Huang, PhD^*, Eric Smith, PhD^*, Gavin Thurston, PhD^* and Jessica R. Kirshner, PhD^*

Regeneron Pharmaceuticals, Tarrytown, NY

5:00 PM

819

Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma

Maciej Szydlowski, PhD¹^*, Monika Prochorec-Sobieszek, MD, PhD¹^*, Anna Szumera-Cieckiewicz, MD, PhD¹^*, Grazyna Hoser, PhD²^*, Ewa Jablonska, PhD¹^*, Emilia Bialopiotrowicz, PhD¹^*, Przemyslaw Kiliszek, MSc¹^*, Tomasz Sewastianik, MSc¹^*, Anna Polak, MSc¹^*, Wojciech Czardybon, PhD³^*, Michal Galezowski, PhD³^*, Renata Windak, PhD³^*, Krzysztof Brzozka, PhD³^*, Krzysztof Warzocha, MD, PhD⁴^*, Jan Maciej Zaucha, MD, PhD⁵ and Przemyslaw Juszczynski, MD, PhD¹

¹Dept. of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
²Dept. of Clinical Cytology, Centre of Postgraduate Medical Education, Warsaw, Poland
³Selvita S.A., Cracow, Poland
⁴Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
⁵Department of Propedeutic Oncology, Medical University of Gdansk and Polish Lymphoma Research Group, Gdynia, Poland

5:15 PM

820

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

Idit Sagiv-Barfi¹^*, Hailing Lu, MD PhD²^*, Jessica Hewitt²^*, Frank J Hsu, MD³, Jan ter Meulen, MD²^* and Ronald Levy, MD⁴

¹Medicine/Oncology, Stanford University, Palo Alto, CA
²Immune Design, Seattle, WA
³Immune Design, South San Francisco, CA
⁴Stanford University, Stanford, CA

5:30 PM

821

Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity

Patrick Hagner, PhD¹^*, Hsiling Chiu¹^*, Maria Ortiz-Estevez²^*, Tsvetan Biyukov³, Carrie Brachman⁴^*, Marek Trneny⁵, Luca Arcaini^6,7^*, Franck Morschhauser, MD⁸^*, Antoine Thyss⁹, Stephan Stilgenbauer¹⁰, Noel Milpied¹¹, Reinhard Marks¹², Pellegrino Musto¹³, Giovanni Martinelli, MD, PhD¹⁴, Carla Heise⁴, Thomas Daniel¹⁵^*, Rajesh Chopra¹, James Carmichael¹⁵^*, Matthew Trotter²^*, Anita K. Gandhi, PhD¹^* and Anjan Thakurta¹^*

¹Celgene Corporation, Summit, NJ
²Celgene Corporation, Sevilla, Spain
³Celgene Corporation, Boudry, Switzerland
⁴Celgene Corporation, San Francisco, CA
⁵Department of Hematology, Charles University Hospital, Prague, Czech Republic
⁶Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
⁷Department of Molecular Medicine, University of Pavia, Pavia, Italy
⁸Hematology Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France
⁹Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
¹⁰Department of Internal Medicine III, Ulm University, Ulm, Germany
¹¹Service d’Hematologie Clinique et Therapie Cellulaire, CHU Haut-Lévêque, Bordeaux, France
¹²Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
¹³Scientific Direction, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture (Pz), Italy
¹⁴Bologna University School of Medicine, Bologna, Italy
¹⁵Celgene Corporation, San Diego, CA

5:45 PM

822

JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1

Hongwei Wang, MD^1,2^*, Fengdong Cheng, MD^1,2^*, Jie Cheng, phD²^*, Alejandro Villagra, phD²^*, Jianguo Tao, MD, PhD², James E. Bradner, MD³ and Eduardo M. Sotomayor, MD^1,2

¹George Washington University, Washington, DC
²H. Lee Moffitt Cancer Center, Tampa, FL
³Harvard Medical School, Boston, MA

See more of: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

625.O2.6 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Immune Modulation and Microenvironment in Lymphoma